<DOC>
	<DOCNO>NCT01142245</DOCNO>
	<brief_summary>The investigator previously show use high-dose intravenous PPI regimen endoscopic control bleed peptic ulcer reduce rate recurrent bleeding , decrease need endoscopic surgical intervention general improve patient ' outcome . A trend towards reduce mortality associate use high-dose intravenous PPI also observe . Recent clinical trial Asia provide evidence high-dose oral PPIs associate reduction rebleeding . Current meta-analysis suggest high dose ( intravenous ) low dose ( oral ) PPIs effectively reduce rebleeding vs placebo . However , clinical study compare IV infusion oral PPI patient population . The purpose clinical study compare efficacy safety intravenous oral Esomeprazole patient peptic ulcer hemorrhage risk recurrent bleeding . The investigator hypothesize use IV infusion superior oral PPI .</brief_summary>
	<brief_title>Effect IV Oral Esomeprazole Prevention Recurrent Bleeding From Peptic Ulcers After Endoscopic Therapy</brief_title>
	<detailed_description>The investigator previously show use high-dose intravenous PPI regimen endoscopic control bleed peptic ulcer reduce rate recurrent bleeding , decrease need endoscopic surgical intervention general improve patient ' outcome . A trend towards reduce mortality associate use high-dose intravenous PPI also observe . Recent clinical trial Asia provide evidence high-dose oral PPIs associate reduction rebleeding . Current meta-analysis suggest high dose ( intravenous ) low dose ( oral ) PPIs effectively reduce rebleeding vs placebo . However , clinical study compare IV infusion oral PPI patient population . Endoscopic stigmata bleed peptic ulcer prognostic allow risk stratification . Patients clean ulcer base &lt; 5 % risk rebleeding ; increase progressively flat spot , adherent clot , non-bleeding visible vessel active bleeding ( 55 % ) . Early endoscopy patient bleed peptic ulcer selects high risk ulcer therapy evaluation adjuvant PPI use .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Peptic Ulcer</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Age â‰¥ 18 Confirmed ulcer bleeding Forrest Ia , Ib , IIa , IIb Endoscopic hemostasis achieve Informed consent obtain No consent Forrest II c , III ( clear ulcer base/flat spot active bleeding , i.e. , minimal risk rebleeding ) Unsuccessful endoscopic treatment ( i.e. , injection and/or thermal coagulation initial bleeding ) severe bleed immediate surgery indicate Moribund patient active treatment form consider . Polytrauma , severe injury , unconsciousness , burn , need continuous artificial ventilation Upper GI malignancy disseminate malignant disease Esophageal varices A MalloryWeiss lesion Phenytoin theophylline treatment Uses PPI H2RAs within 3 day admission , include us Emergency Department N.B . Usage aspirin NSAID exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>ulcer bleeding</keyword>
	<keyword>endoscopic therapy</keyword>
</DOC>